Biomedical Engineering Reference
In-Depth Information
and patient characteristics upon warfarin dose requirements: proposal for a new dosing
regimen. Blood 106:2329-2333.
7. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thum-
mel KE, Veenstra DL, Rettie AE. 2005. Effect of VKORC1 haplotypes on transcriptional
regulation and warfarin dose. N Engl J Med 352:2285-2293.
8. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I,
Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of
the human multidrug-resistance gene: multiple sequence variations and correlation of
one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad SciUSA
97:3473-3478.
9. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG,
McKinsey J, Zhou S, et al. 2001. Identification of functionally variant
MDR1
alleles
among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
10. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D,
Ferrin TE, DeYoung J, Taylor T, et al. 2003. Sequence diversity and haplotype structure
in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics
13:481-494.
11. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-
glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
12. Pauli-Magnus C, Kroetz DL. 2004. Functional implications of genetic polymorphisms in
the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21:904-913.
13. Schwab M, Eichelbaum M, Fromm MF. 2003. Genetic polymorphisms of the human
MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307.
14. Sakaeda T, Nakamura T, Okumura K. 2003. Pharmacogenetics of MDR1 and its impact
on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397-
410.
15. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S,
Mullikin JC, Mortimore BJ, Willey DL, et al. 2001. A map of human genome sequence
variation containing 1.42 million single-nucleotide polymorphisms. Nature 409:928-933.
16. Allabi AC, Horsmans Y, Issaoui B, Gala JL. 2005. Single nucleotide polymorphisms of
ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population.
Eur J Clin Pharmacol 61:97-102.
17. Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadee W. 2006. Genetic
variants of the human dipeptide transporter PEPT1. J Pharmacol Exp Ther 316:636-646.
18. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns
SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. 2005. Functional analysis of
genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
Pharmacogenom J 5:157-165.
19. Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB. 2005. Functional con-
sequences of single-nucleotide polymorphisms in the human organic anion transporter
hOAT1 (SLC22A6). J Pharmacol Exp Ther 314:923-931.
20. Damaraju S, Zhang J, Visser F, Tackaberry T, Dufour J, Smith KM, Slugoski M, Ritzel
MW, Baldwin SA, Young JD, Cass CE. 2005. Identification and functional characteri-
zation of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3),
arising from single-nucleotide polymorphisms in coding regions of the hCNT3 gene.
Pharmacogenet Genom 15:173-182.
Search WWH ::
Custom Search